Role of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions

Efficacy of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions Clinical Trial

Official title:

Role of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03463291
• Other study ID #: MRIBMBL
• Status: Not yet recruiting
• Phase: N/A
• First received: March 6, 2018
• Last updated: March 10, 2018
• Start date: May 2018
• Est. completion date: July 2020

Study information

• Verified date: March 2018
• Source: Assiut University
• Contact: Amr M Attia
• Phone: +201270092886
• Email: hexen_22us[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Bone tumors are categorized according to their tissue of origin into cartilagenous, osteogenic, fibrogenic, fibrohistiocytic, haematopoietic, vascular, and lipogenic tumors.

Magnetic resonance imaging (MRI) is now indispensable for the preoperative workup and therapeutic follow-up of patients with musculoskeletal tumors.

The application of DW-MRI in bone marrow is today an established examination technique that provides a unique contrast and that can help in the detection of bone-marrow pathologies and the differentiation of benign and malignant bone-marrow lesions.

Diffusion MRI provides quantitative and qualitative assessments of tissue cellularity and cell-membrane integrity. It is widely used for tumour detection, characterisation, and monitoring during treatment. Diffusion MRI supplies functional information that complements the structural evaluation.

In combination with standard structural MRI parameters, the ADC value improves tumour characterization. Diffusion MRI can also be used to monitor tumours during chemotherapy. Tumour necrosis results in loss of cell membrane integrity and in expansion of the extracellular compartment, leading to greater water-molecule diffusion with an increase in the ADC value.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: July 2020
• Est. primary completion date: May 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients with bony lesions will be included in the study.

Exclusion Criteria:

• Patient with cardiac pacemaker.

• Patients with metallic prosthesis in the region of examination.

• Patients with claustrophobia.

• Patient with recent history of surgical or imagining guided biopsy from the bony lesion.

Related Conditions & MeSH terms

• Efficacy of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions

Intervention

Device:
• MRI
T1 weighted image. Fast spin-echoT2 weighted image. Short inversion recovery (STIR). T1-fat suppressed images. Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The ADC value of MRI diffusion in benign and malignant bony lesions ( considering ADC value <1.2 ..malignant while ADC>1.2 ..benign)		1 day